EconStor >
United Nations University (UNU) >
World Institute for Development Economics Research (UNU-WIDER), United Nations University >
WIDER Research Papers, United Nations University (UNU) >

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10419/45100
  

Full metadata record

DC FieldValueLanguage
dc.contributor.authorLi, Xuanen_US
dc.date.accessioned2010-02-15en_US
dc.date.accessioned2011-04-26T07:40:50Z-
dc.date.available2011-04-26T07:40:50Z-
dc.date.issued2008en_US
dc.identifier.isbn978-92-9230-082-1en_US
dc.identifier.urihttp://hdl.handle.net/10419/45100-
dc.description.abstractA comparative study is undertaken that explores Chinese and Indian pharmaceutical industries under different patent regimes. It is found that relative to India, which had implemented process patent until 2005, China with a product patent regime since 1993 suffers from both lower drug accessibility and availability (the latter is a missing parameter in the literature). Also, China lags behind in both lower R&D investment and patents filed by Chinese nationals. Based on these findings and associated legal interpretation, we conclude that higher patent protection in China generates negative impacts on the pharmaceutical industries. Thus, governments should utilize TRIPS flexibilities and other regimes like price control to offset the anticompetitive effect in designing patent policies.en_US
dc.language.isoengen_US
dc.publisherUNU-WIDER Helsinkien_US
dc.relation.ispartofseriesResearch paper / UNU-WIDER 2008.36en_US
dc.subject.jelO34en_US
dc.subject.jelL65en_US
dc.subject.jelF14en_US
dc.subject.ddc330en_US
dc.subject.keywordproduct patenten_US
dc.subject.keywordprocess patenten_US
dc.subject.keywordTRIPSen_US
dc.subject.keywordpharmaceutical industriesen_US
dc.subject.keywordChinaen_US
dc.subject.keywordIndiaen_US
dc.subject.stwTRIPSen_US
dc.subject.stwPatentrechten_US
dc.subject.stwWohlfahrtseffekten_US
dc.subject.stwPharmazeutische Industrieen_US
dc.subject.stwChinaen_US
dc.subject.stwIndienen_US
dc.titleThe impact of higher standards in patent protection for pharmaceutical industries under the TRIPS Agreement: A comparative study of China and Indiaen_US
dc.typeWorking Paperen_US
dc.identifier.ppn571446388en_US
dc.rightshttp://www.econstor.eu/dspace/Nutzungsbedingungenen_US
Appears in Collections:WIDER Research Papers, United Nations University (UNU)

Files in This Item:
File Description SizeFormat
571446388.pdf166.11 kBAdobe PDF
No. of Downloads: Counter Stats
Show simple item record
Download bibliographical data as: BibTeX

Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.